Recce Pharmaceuticals Ltd
ASX:RCE

Watchlist Manager
Recce Pharmaceuticals Ltd Logo
Recce Pharmaceuticals Ltd
ASX:RCE
Watchlist
Price: 0.595 AUD -2.46% Market Closed
Updated: May 20, 2024

Recce Pharmaceuticals Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Recce Pharmaceuticals Ltd
Revenue Peer Comparison

Comparables:
MYX
NEU
BOT
PBP
C
CU6

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Recce Pharmaceuticals Ltd
ASX:RCE
Revenue
AU$6.8m
CAGR 3-Years
104%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Revenue
AU$190.3m
CAGR 3-Years
-25%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Revenue
AU$237.6m
CAGR 3-Years
550%
CAGR 5-Years
77%
CAGR 10-Years
47%
Botanix Pharmaceuticals Ltd
ASX:BOT
Revenue
AU$588.4k
CAGR 3-Years
56%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Probiotec Ltd
ASX:PBP
Revenue
AU$221.2m
CAGR 3-Years
28%
CAGR 5-Years
24%
CAGR 10-Years
13%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Revenue
AU$11.7m
CAGR 3-Years
59%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Recce Pharmaceuticals Ltd's Revenue?
Revenue
6.8m AUD

Based on the financial report for Dec 31, 2023, Recce Pharmaceuticals Ltd's Revenue amounts to 6.8m AUD.

What is Recce Pharmaceuticals Ltd's Revenue growth rate?
Revenue CAGR 5Y
34%

Over the last year, the Revenue growth was 115%. The average annual Revenue growth rates for Recce Pharmaceuticals Ltd have been 104% over the past three years , 34% over the past five years .